CClinicalTrials.gg
Status unknownNCT04270721EAGLEUpdated Sep 29, 2021

ESCP Safe Anastomosis proGramme in coLorectal surgEry

An interventional study of The EAGLE Safe Anastomosis Quality Improvement Intervention in Anastomotic Leak and Anastomosis; Complications, sponsored by University of Birmingham. Status unknown at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by University of Birmingham · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
4,400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

EAGLE is an international service improvement study to investigate the value of an educational tool delivered to surgeons and their teams to reduce the risk of anastomotic leak (leak of a join in the bowel) after right hemicolectomy or ileocaecal resection. This complication causes significant risk to life and therefore risks of leak should be minimised.

The educational team of the European Society of Coloproctology has developed an online training package to deliver to 350 hospitals in 30 countries.

Read the detailed description

EAGLE is an international quality improvement programme to share best practice and harmonise ileo-colic anastomosis procedures through an education programme for surgeons and theatre teams.

The programme has 3 main strategies: (i) enhanced pre-operative risk stratification (making sure it is safe to join the bowel together for each patient); (ii) harmonisation of surgical technique (making the join as good as it can be and checking it carefully after it is created), and (iii) implementation of an intra-operative anastomosis 'checklist' (focusing the attention of the whole theatre team at this critical stage of the operation). The investigators will use a novel scientific approach to assess the patient benefit that enables not only the quality improvement itself to be delivered to all participating hospitals but also enables collection and analysis of data to measure the effect of these measures. The best way of doing this is to embed the proposed quality improvement into a staggered implementation programme, allowing the effect to be assessed between the centres. The specific methodology proposed introduces the intervention in a step-wise fashion to all hospitals. By the end, all sites will have implemented the programme. Overall, the investigators hope to reduce the leak rate by 30% from 8.1% to 5.6% in about 4,500 patients.

02

Conditions studied

  • Anastomotic Leak
  • Anastomosis; Complications

Browse trials for

Keywords

  • anastomotic leak
  • right colectomy
  • cluster randomised study
  • leak prediction
03

In context

Anastomotic Leak

209 studies on the registry are indexed under Anastomotic Leak; 60 are open to participants now.

This study's planned enrollment of 4,400 is above the median of 121 across 100 interventional studies indexed under Anastomotic Leak.

Browse Anastomotic Leak studies →

Lead sponsor

University of Birmingham is the lead sponsor of 179 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All adult patients (age 18 years and above) undergoing right colectomy with or without primary anastomosis. Right colectomy is defined as ileocaecal resection or right hemicolectomy (any colonic transection with the distal resection margin proximal to the splenic flexure).
  • All patients undergoing right colectomy are eligible, including those who do not have an anastomosis and are defunctioned by a proximal stoma.
  • Procedures for any pathology, via any operative approach (open, laparoscopic, robotic or converted) are eligible.
  • Elective (surgery on a planned admission), expedited, and emergency (surgery on an unplanned admission) procedures are eligible.

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing more than one gastrointestinal anastomosis during the same operation.
  • In Crohn's disease, additional upstream stricturoplasty or resection/anastomosis to treat disease or strictures at the same operation.
  • Simultaneous right colectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) and/or cytoreductive surgery.
  • Each individual patient should only be included in EAGLE once. Following the index procedure that is included in EAGLE, patients undergoing additional procedures within the study window should not be included for a second time.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
4,400 participants (estimated)

Study arms

  • Experimental
    After intervention (sequence 1)

    'After intervention' group receives the training immediately and data are only collected after the intervention.

    Behavioral: The EAGLE Safe Anastomosis Quality Improvement Intervention

  • Experimental
    Before and after intervention (sequence 2)

    For the 'Before and after intervention' group, data are collected both before and after the training.

    Behavioral: The EAGLE Safe Anastomosis Quality Improvement Intervention

  • No intervention
    Before intervention (sequence 3)

    The 'before intervention' group collects data only before the training. \*This arm will receive the educational intervention after data collection is completed.

Interventions

  • BehavioralThe EAGLE Safe Anastomosis Quality Improvement Intervention

    The intervention is the same in each arm; the EAGLE Safe Anastomosis Quality Improvement Intervention is an educational programme for behavioural change composed of three parts: 1. Introduction of a routine patient risk stratification for anastomotic leak 2. Implementation of the ESCP Safe Anastomosis Checklist 3. Adoption of a harmonised technique for stapled and handsewn anastomosis based on best evidence.

06

What researchers measure

Primary outcomes

  1. Number of patients diagnosed clinically or radiologically with anastomotic leak within 30 days of surgery

    Anastomotic leak is defined as anastomotic leak identified radiologically or clinically, or intra-peritoneal (abdominal or pelvic) fluid collection identified radiologically, as per the Centre for Disease Control Criteria for Organ Space infection. This will be described as a rate divided by the total number of patients who had a primary anastomosis (rather than total number of patients undergoing right hemicolectomy or ileocaecal resection).

    Time frame: up to 30 days from operation

Secondary outcomes

  1. The rate of re-operation for anastomotic leak

    The number of patients re-operated, of those diagnosed with anastomotic leak following right hemicolectomy or ileocaecal resection

    Time frame: up to 30 days

  2. The rate of adverse outcomes following right hemicolectomy or ileocaecal resection

    For all patients included in the study (i.e. who underwent right hemicolectomy or ileocaecal resection whether or not with primary anastomosis); 1. Number of patients undergoing re-operation for any cause within 30 days 2. Number of patients with unplanned admission to critical care within 30 days 3. Number of patients re-admitted to hospital within 30 days 4. Mortality rate within 30 days

    Time frame: up to 30 days

  3. The rate of stoma formation

    For all patients included in the study (i.e. who underwent right hemicolectomy or ileocaecal resection whether or not with primary anastomosis); 1. Rate of formation of ileostomy without primary anastomosis 2. Rate of defunctioning ileostomy with primary anastomosis

    Time frame: At index operation

  4. Length of hospital stay following right hemicolectomy or ileocaecal resection

    Measured in post-operative days

    Time frame: up to 30 days

Other outcomes

  1. Feasibility of recruitment of clusters (hospitals) in this study design

    Measured by the number of participating hospitals and countries

    Time frame: Through to study completion, expected 1 year

  2. Time to site set-up in this study design

    Time taken for study set-up at sites from registration to randomisation

    Time frame: Through to study completion, expected 1 year

  3. Uptake of online educational modules

    The proportion of eligible surgeons to undertake the educational modules in participating units.

    Time frame: Through to study completion, expected 1 year

  4. Understanding uptake and effectiveness of online educational modules

    Semi-structured interviews will be undertaken at purposefully sampled units to assess longevity of the intervention

    Time frame: Surgeons will have 30 days to complete the educational evaluation to collect CPD (continuing professional development) certificate. Interviews will take place 3-6 months after study completion at individual units.

  5. Adherence to implementation of the Safe Anastomosis Programme

    The proportion of eligible patients whose team completed the pre-operative risk stratification and Safe Anastomosis Checklist

    Time frame: day of index operation

07

Study locations

1 of 1 sites recruiting
  • Clinic of Coloproctology and Minimally Invasive Surgery
    Moscow, Russian Federation
    • Tatiana Gormanova · Contact
    Recruiting
08

References and documents

Publications

  • ESCP EAGLE Safe Anastomosis Collaborative. ESCP Safe Anastomosis ProGramme in CoLorectal SurgEry (EAGLE): Study protocol for an international cluster randomised trial of a quality improvement intervention to reduce anastomotic leak following right colectomy. Colorectal Dis. 2021 Oct;23(10):2761-2771. doi: 10.1111/codi.15806. Epub 2021 Aug 25. PubMed 34255417 ↗

Individual participant data

Plan to share: Yes — The investigators anticipate that the study protocol will be published early 2020. The Clinical Study report will be published most likely in 2021. This study will not collect patient identifiable data. All 'individual participant data' will be anonymised.

Supporting information: Study protocol, Sap

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04270721
Lead sponsor
University of Birmingham
Collaborators
Ethicon, Inc., European Society of Coloproctology
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Feb 3, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Jul 1, 2022 (estimated)
Last update
Sep 29, 2021

Study contacts

James Keatley
Contact
J.Keatley@bham.ac.uk
+44 (0)121 371 8026
Brett Dawson
Contact
B.Dawson@bham.ac.uk
+44 (0) 121 371 8140
Dion Morton
principal investigator · University of Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion